Dowling & Yahnke’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $4.76M | Buy |
59,056
+88
| +0.1% | +$7.45K | 0.22% | 109 |
|
|
2022
Q2 | $4.39M | Buy |
58,968
+8,096
| +16% | +$739K | 0.21% | 115 |
|
|
2022
Q1 | $6.51M | Sell |
50,872
-5,108
| -9% | -$559K | 0.28% | 94 |
|
|
2021
Q4 | $7.51M | Buy |
55,980
+152
| +0.3% | +$21.8K | 0.36% | 85 |
|
|
2021
Q3 | $7.63M | Buy |
55,828
+52
| +0.1% | +$6.56K | 0.42% | 74 |
|
|
2021
Q2 | $5.95M | Buy |
55,776
+3,224
| +6% | +$310K | 0.34% | 88 |
|
|
2021
Q1 | $4.72M | Buy |
52,552
+36
| +0.1% | +$3.38K | 0.32% | 94 |
|
|
2020
Q4 | $4.85M | Buy |
52,516
+32
| +0.1% | +$2.86K | 0.35% | 86 |
|
|
2020
Q3 | $5.41M | Sell |
52,484
-136,000
| -72% | -$14.2M | 0.43% | 72 |
|
|
2020
Q2 | $19.1M | Buy |
188,484
+2,864
| +2% | +$256K | 1.6% | 8 |
|
|
2020
Q1 | $12.5M | Sell |
185,620
-10,016
| -5% | -$623K | 1.2% | 16 |
|
|
2019
Q4 | $10.7M | Sell |
195,636
-9,984
| -5% | -$474K | 0.82% | 28 |
|
|
2019
Q3 | $7.67M | Sell |
205,620
-10,000
| -5% | -$389K | 0.63% | 49 |
|
|
2019
Q2 | $8.08M | Buy |
215,620
+3,796
| +2% | +$119K | 0.67% | 46 |
|
|
2019
Q1 | $6.31M | Sell |
211,824
-10,000
| -5% | -$351K | 0.61% | 55 |
|
|
2018
Q4 | $7.19M | Sell |
221,824
-10,000
| -4% | -$317K | 0.74% | 40 |
|
|
2018
Q3 | $8.29M | Sell |
231,824
-19,596
| -8% | -$608K | 0.72% | 37 |
|
|
2018
Q2 | $5.97M | Buy |
251,420
+17,412
| +7% | +$369K | 0.55% | 60 |
|
|
2018
Q1 | $4.34M | Hold |
234,008
| – | – | 0.41% | 82 |
|
|
2017
Q4 | $3.36M | Buy |
234,008
+140,000
| +149% | +$1.82M | 0.3% | 102 |
|
|
2017
Q3 | $1.15M | Sell |
94,008
-72
| -0.1% | -$1.27K | 0.12% | 170 |
|
|
2017
Q2 | $1.72M | Buy |
94,080
+19,236
| +26% | +$355K | 0.18% | 140 |
|
|
2017
Q1 | $1.58M | Hold |
74,844
| – | – | 0.17% | 149 |
|
|
2016
Q4 | $1.12M | Buy |
74,844
+14,276
| +24% | +$253K | 0.12% | 163 |
|
|
2016
Q3 | $1.33M | Sell |
60,568
-14,000
| -19% | -$312K | 0.16% | 151 |
|
|
2016
Q2 | $1.48M | Buy |
74,568
+17,116
| +30% | +$291K | 0.18% | 139 |
|
|
2016
Q1 | $975K | Hold |
57,452
| – | – | 0.12% | 162 |
|
|
2015
Q4 | $1.18M | Buy |
57,452
+14,276
| +33% | +$297K | 0.15% | 145 |
|
|
2015
Q3 | $927K | Sell |
43,176
-20,000
| -32% | -$446K | 0.13% | 154 |
|
|
2015
Q2 | $1.26M | Buy |
63,176
+25,848
| +69% | +$454K | 0.16% | 141 |
|
|
2015
Q1 | $582K | Hold |
37,328
| – | – | 0.07% | 186 |
|
|
2014
Q4 | $514K | Buy |
37,328
+14,280
| +62% | +$175K | 0.06% | 192 |
|
|
2014
Q3 | $230K | Hold |
23,048
| – | – | 0.03% | 234 |
|
|
2014
Q2 | $229K | Buy |
23,048
+3,048
| +15% | +$27K | 0.03% | 249 |
|
|
2014
Q1 | $207K | Buy |
+20,000
| New | +$207K | 0.03% | 264 |
|
Other funds holding DXCM
Dowling & Yahnke's DXCM Position: Q3 2022 in Review
Dowling & Yahnke increased its DexCom (DXCM) stake by 0.15% in Q3 2022, buying an estimated $7.45K and bringing the position to 59,056 shares worth $4.76M. The position accounts for 0.22% of the portfolio, ranked #109.
Dowling & Yahnke first reported a position in DXCM in Q1 2014 and has held it in 35 quarters since. The position peaked at $19.1M in Q2 2020. 795 funds tracked by Wall St. Rank hold DXCM as of Q3 2022.
- Dowling & Yahnke held 59,056 shares of DexCom worth $4.76M as of Q3 2022.
- Dowling & Yahnke bought 88 DexCom shares in Q3 2022, an estimated $7.45K.
- DexCom made up 0.22% of Dowling & Yahnke's portfolio in Q3 2022, its #109 holding.
- Dowling & Yahnke first reported a position in DexCom in Q1 2014 and has held it in 35 quarters since.
- Dowling & Yahnke's DexCom position peaked at $19.1M in Q2 2020.
- 795 funds tracked by Wall St. Rank held DexCom as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.